In a pilot prospective , randomized , double-blinded , placebo-controlled trial , we studied whether 14 days of pretransplant donor treatment with valganciclovir ( valG ) versus placebo reduced donor-to-recipient transmission , making posttransplant recipient prophylaxis more effective in reducing EBV and CMV disease .